​

Oruka Therapeutics (ORKA) Stock Forecast, Price Target & Predictions

OverviewOwnershipChart

ORKA Stock Forecast

Oruka Therapeutics (ORKA) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $53.00, with a high of $75.00 and a low of $40.00. This represents a 64.24% increase from the last price of $32.27.

ORKA Stock Rating

Oruka Therapeutics stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

ORKA Price Target Upside V Benchmarks

TypeNameUpside
StockOruka Therapeutics64.24%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-36
Avg Price Target-$56.67$53.00
Last Closing Price$32.27$32.27$32.27
Upside/Downside-75.61%64.24%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 26211---13
Jan, 26210---12
Dec, 25110---11
Nov, 2529---11
Oct, 2518---9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 13, 2026Wedbush$45.00$30.2848.61%39.45%
Jan 07, 2026Michael YeeUBS$50.00$26.6287.83%54.94%
Dec 18, 2025Piper Sandler$75.00$28.38164.27%132.41%
Oct 27, 2025Guggenheim$60.00$27.25120.18%85.93%
Oct 27, 2025Mitchell KapoorH.C. Wainwright$40.00$27.2546.79%23.95%
Oct 13, 2025Barclays$48.00$24.4996.00%48.74%
Feb 04, 2025Andy ChenWolfe Research$20.00$13.7045.99%-38.02%
Sep 12, 2024Michael YeeJefferies$40.00$26.0053.85%23.95%
Sep 04, 2024David NierengartenWedbush$40.00$25.5056.86%23.95%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 13, 2026WedbushOutperformOutperformhold
Jan 07, 2026UBSBuyinitialise
Dec 18, 2025Piper SandlerOverweightinitialise
Oct 27, 2025GuggenheimBuyinitialise
Oct 27, 2025H.C. WainwrightBuyBuyhold
Oct 13, 2025BarclaysOverweightinitialise
May 22, 2025BTIGBuyinitialise
Feb 04, 2025Wolfe ResearchOutperforminitialise
Oct 07, 2024H.C. WainwrightBuyinitialise
Sep 25, 2024Cowen & Co.BuyBuyhold

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 $-1 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-4.99-----
Avg Forecast$-3.41$-2.34$-2.56$-2.23$-2.84$-2.73
High Forecast$-1.56$-1.27$-1.41$-2.23$-2.84$-2.73
Low Forecast$-4.86$-6.90$-4.33$-2.23$-2.84$-2.73
Surprise %46.33%-----

Revenue Forecast

Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported------
Avg Forecast------
High Forecast------
Low Forecast------
Surprise %------

Net Income Forecast

$-120M $-100M $-80M $-60M $-40M $-20M Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-83.72M-----
Avg Forecast$-53.88M$-108.38M$-48.23M$-37.44M$-47.74M$-45.75M
High Forecast$-26.18M$-21.39M$-23.72M$-37.44M$-47.74M$-45.75M
Low Forecast$-81.57M$-115.84M$-72.74M$-37.44M$-47.74M$-45.75M
Surprise %55.40%-----

ORKA Forecast FAQ

Is Oruka Therapeutics stock a buy?

Oruka Therapeutics stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Oruka Therapeutics is a favorable investment for most analysts.

What is Oruka Therapeutics's price target?

Oruka Therapeutics's price target, set by 4 Wall Street analysts, averages $53 over the next 12 months. The price target range spans from $40 at the low end to $75 at the high end, suggesting a potential 64.24% change from the previous closing price of $32.27.

How does Oruka Therapeutics stock forecast compare to its benchmarks?

Oruka Therapeutics's stock forecast shows a 64.24% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Oruka Therapeutics over the past three months?

  • February 2026: 15.38% Strong Buy, 84.62% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 16.67% Strong Buy, 83.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 9.09% Strong Buy, 90.91% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Oruka Therapeutics’s EPS forecast?

Oruka Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.34, marking a -53.11% decrease from the reported $-4.99 in 2024. Estimates for the following years are $-2.56 in 2026, $-2.23 in 2027, $-2.84 in 2028, and $-2.73 in 2029.

What is Oruka Therapeutics’s revenue forecast?

Oruka Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $0, followed by $0 for 2027, $0 for 2028, and $0 for 2029.

What is Oruka Therapeutics’s net income forecast?

Oruka Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-108M, representing an 29.44% increase from the reported $-83.724M in 2024. Projections indicate $-48.231M in 2026, $-37.44M in 2027, $-47.738M in 2028, and $-45.751M in 2029.